|
nasopharyngeal carcinoma |
93 |
|
humans |
64 |
|
male |
46 |
|
female |
42 |
|
middle aged |
42 |
|
adult |
36 |
|
aged |
33 |
|
radiotherapy |
29 |
|
medical sciences |
27 |
|
epstein-barr virus |
24 |
|
whole-exome sequencing |
24 |
|
neoplasm staging |
23 |
|
chemoradiotherapy |
22 |
|
prognosis |
21 |
|
aged, 80 and over |
18 |
|
chinese |
18 |
|
neoplasm metastasis |
18 |
|
quality of life |
18 |
|
disease-free survival |
17 |
|
dna methylation |
17 |
|
oncology |
17 |
|
prognostic factors |
17 |
|
animals |
16 |
|
disease progression |
16 |
|
follow-up studies |
16 |
|
respiratory system - virology |
16 |
|
treatment outcome |
16 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
15 |
|
chemotherapy, adjuvant |
15 |
|
cisplatin |
15 |
|
intensity-modulated radiation therapy |
15 |
|
adolescent |
14 |
|
combined modality therapy |
14 |
|
prospective studies |
14 |
|
radiotherapy, adjuvant |
14 |
|
tumor microenvironment |
14 |
|
cancer susceptibility genes |
13 |
|
carcinoma, squamous cell - genetics - metabolism - pathology |
13 |
|
china |
13 |
|
conjunctiva - virology |
13 |
|
early-age onset |
13 |
|
efficacy |
13 |
|
emt |
13 |
|
esophageal neoplasms - genetics - metabolism - pathology |
13 |
|
esophageal squamous cell carcinoma |
13 |
|
gastric cancer |
13 |
|
mst1r |
13 |
|
nasopharyngeal carcinoma (npc) |
13 |
|
radiotherapy dosage |
13 |
|
apobec-mediated signature |
12 |
|
bronchi - cytology |
12 |
|
capecitabine |
12 |
|
chi-square distribution |
12 |
|
influenza a virus, h1n1 subtype - metabolism |
12 |
|
influenza, human - virology |
12 |
|
neoadjuvant therapy |
12 |
|
nf-κb signaling |
12 |
|
promoter hypermethylation |
12 |
|
somatic mutation landscape |
12 |
|
survival analysis |
12 |
|
treatment outcomes |
12 |
|
tumor cells, cultured |
12 |
|
analysis of variance |
11 |
|
case-control studies |
11 |
|
chemotherapy |
11 |
|
esophageal squamous cell carcinoma (escc) |
11 |
|
liquid biopsy |
11 |
|
lymphatic metastasis |
11 |
|
metastasis |
11 |
|
methylation |
11 |
|
nidogen-2 (nid2) |
11 |
|
npc |
11 |
|
safety |
11 |
|
survival |
11 |
|
t-lymphocytes, cytotoxic - immunology |
11 |
|
accelerated fractionation |
10 |
|
arhgap fusions |
10 |
|
biobank |
10 |
|
case-control study |
10 |
|
colorectal cancer |
10 |
|
cross-sectional studies |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
esophagectomy |
10 |
|
heterogeneity |
10 |
|
hong kong |
10 |
|
influenza a virus, h1n1 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h1n2 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h5n1 subtype - metabolism |
10 |
|
influenza, human - metabolism - transmission |
10 |
|
intensity-modulated radiotherapy |
10 |
|
organ culture techniques |
10 |
|
organoid culture |
10 |
|
plasma ebv dna |
10 |
|
promoter regions, genetic |
10 |
|
radiation |
10 |
|
randomized controlled trial |
10 |
|
reassortant viruses - isolation & purification |
10 |
|
receptors, cell surface - metabolism |
10 |
|
respiratory mucosa - virology |
10 |
|
rhoa mutations |
10 |
|
statistics, nonparametric |
10 |
|
survival rate |
10 |
|
swine |
10 |
|
transcriptome sequencing |
10 |
|
viral tropism |
10 |
|
virulence |
10 |
|
virus attachment |
10 |
|
25-hydroxyvitamin d |
9 |
|
chromatin accessibility |
9 |
|
covid-19 |
9 |
|
dietary fiber |
9 |
|
dose-response relationship, radiation |
9 |
|
dual specificity phosphatase 6 - genetics - metabolism |
9 |
|
dual-specificity phosphatase 6 (dusp6) |
9 |
|
epidemiology |
9 |
|
epithelial-mesenchymal transition |
9 |
|
esophageal cancer |
9 |
|
fact-c |
9 |
|
fresh vegetable and fruit |
9 |
|
genetic epidemiology |
9 |
|
genetic variant |
9 |
|
host-virus interaction |
9 |
|
imrt |
9 |
|
in situ hybridization, fluorescence |
9 |
|
leucocyte telomere length |
9 |
|
life-course |
9 |
|
milk |
9 |
|
multiple imputation |
9 |
|
nasopharyngeal neoplasms - genetics - metabolism - pathology |
9 |
|
nasopharyngeal neoplasms - radiotherapy |
9 |
|
npc risk |
9 |
|
preserved food |
9 |
|
prognostic marker |
9 |
|
radiology and nuclear medicine |
9 |
|
recursive partitioning analysis |
9 |
|
reverse transcriptase polymerase chain reaction |
9 |
|
soybean product |
9 |
|
stage classification |
9 |
|
surgery |
9 |
|
survival prediction |
9 |
|
telomere biology |
9 |
|
tumor suppression |
9 |
|
tumor suppressor |
9 |
|
ultraviolet radiation |
9 |
|
vitamin d |
9 |
|
vitamin d deficiency |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
xerostomia |
9 |
|
adaptor proteins, signal transducing - physiology |
8 |
|
antiangiogenesis |
8 |
|
apoptosis |
8 |
|
bintrafusp alfa |
8 |
|
carcinoma - radiotherapy |
8 |
|
cell differentiation |
8 |
|
cell transformation, neoplastic - genetics |
8 |
|
child |
8 |
|
chromosomes, human, pair 9 - genetics |
8 |
|
cigarette smoking |
8 |
|
circulating neoplastic cell |
8 |
|
circulating tumor dna |
8 |
|
correlative biomarkers |
8 |
|
cranial irradiation - adverse effects |
8 |
|
cytokines - genetics - physiology |
8 |
|
cytology and histology |
8 |
|
dose fractionation |
8 |
|
dose-response relation |
8 |
|
dosimetric predictors |
8 |
|
esophageal carcinoma |
8 |
|
gene expression regulation, neoplastic |
8 |
|
head and neck cancers |
8 |
|
herpesvirus 4, human - immunology |
8 |
|
hong kong - epidemiology |
8 |
|
hypothyroidism |
8 |
|
immunotherapy |
8 |
|
incidence |
8 |
|
longitudinal real-time monitoring |
8 |
|
multivariate analysis |
8 |
|
neovascularization, pathologic - genetics |
8 |
|
nf-kappa b - metabolism |
8 |
|
non-invasive biomarker |
8 |
|
non-metastatic |
8 |
|
oesophageal cancer |
8 |
|
oesophageal squamous cell carcinoma |
8 |
|
oesophagectomy |
8 |
|
oncology medical sciences |
8 |
|
polymerase chain reaction |
8 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
8 |
|
recurrence |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
salivation - radiation effects |
8 |
|
sex factors |
8 |
|
smoking cessation |
8 |
|
time factors |
8 |
|
transcription regulator |
8 |
|
advanced escc |
7 |
|
age factors |
7 |
|
anchor |
7 |
|
anti-angiogenic |
7 |
|
asian continental ancestry group |
7 |
|
azygos vein blood |
7 |
|
biomarker |
7 |
|
biopsy |
7 |
|
blm |
7 |
|
cancer chemotherapy |
7 |
|
ccdc170 |
7 |
|
cell line, tumor |
7 |
|
cell-free dna |
7 |
|
chromosome aberrations |
7 |
|
circulating tumor cells |
7 |
|
circulating tumor cells (ctc) |
7 |
|
colorectal neoplasm |
7 |
|
cost-of-illness |
7 |
|
ctc clusters |
7 |
|
ctc enumeration |
7 |
|
direct medical cost |
7 |
|
dna dsb repair |
7 |
|
early prediction |
7 |
|
epidermal growth factor receptor |
7 |
|
familial npc |
7 |
|
fibulin-2 |
7 |
|
genetic susceptibility |
7 |
|
health care service provider |
7 |
|
herpesvirus 4, human - genetics |
7 |
|
immune checkpoint inhibitors |
7 |
|
loss of heterozygosity |
7 |
|
nasopharyngeal neoplasms |
7 |
|
nhej |
7 |
|
non-small-cell lung cancer |
7 |
|
parotid sparing |
7 |
|
pathway associations |
7 |
|
pilot projects |
7 |
|
positron emission tomography |
7 |
|
prognostic factor |
7 |
|
prognostication |
7 |
|
radiation injuries - complications |
7 |
|
radiation therapy |
7 |
|
responsiveness |
7 |
|
risk factors |
7 |
|
service utilization |
7 |
|
sf-12 |
7 |
|
targeted therapy |
7 |
|
tert |
7 |
|
tumor suppressor gene |
7 |
|
tyrosine kinase inhibitors |
7 |
|
vegf |
7 |
|
adherens junctions - metabolism |
6 |
|
alpha b-crystallin |
6 |
|
blotting, western |
6 |
|
cadherins - metabolism |
6 |
|
cancer |
6 |
|
carcinoma |
6 |
|
carcinoma - metabolism - pathology |
6 |
|
china - epidemiology |
6 |
|
comparative genomic hybridization |
6 |
|
concurrent chemoradiotherapy |
6 |
|
confirmatory factor analysis |
6 |
|
ctc |
6 |
|
cxcl8 |
6 |
|
cxcr2 |
6 |
|
e-cadherin |
6 |
|
early diagnosis |
6 |
|
escc |
6 |
|
fatal outcome |
6 |
|
follow up |
6 |
|
gene expression |
6 |
|
half-life clearance |
6 |
|
health care |
6 |
|
image processing, computer-assisted |
6 |
|
immunoenzyme techniques |
6 |
|
induction chemotherapy |
6 |
|
local clinical remission |
6 |
|
lymph node metastasis |
6 |
|
lymph nodes - pathology |
6 |
|
measurement invariance |
6 |
|
metastatic |
6 |
|
mice |
6 |
|
mif |
6 |
|
mode of administration |
6 |
|
ms‐hrm |
6 |
|
multidisciplinary |
6 |
|
nasopharyngeal cancer |
6 |
|
nasopharyngeal neoplasms - metabolism - pathology |
6 |
|
non-small cell lung cancer |
6 |
|
oral health |
6 |
|
pediatric |
6 |
|
pharyngectomy |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
post-treatment plasma ebv dna |
6 |
|
postradiation malignancies |
6 |
|
reliability |
6 |
|
retrospective studies |
6 |
|
salivary flow |
6 |
|
squamous cell carcinoma |
6 |
|
survivorship |
6 |
|
thyroid cancer |
6 |
|
tomography, x-ray computed |
6 |
|
tomography, x-ray computed - methods |
6 |
|
tumor markers, biological - blood |
6 |
|
tumor suppressor proteins - metabolism |
6 |
|
tumour spheres |
6 |
|
twist1 |
6 |
|
validity |
6 |
|
xenograft |
6 |
|
β-catenin |
6 |
|
adenoviridae - immunology |
5 |
|
aetiology |
5 |
|
algorithms |
5 |
|
antineoplastic agents |
5 |
|
antineoplastic agents - therapeutic use |
5 |
|
autoimmune disease |
5 |
|
cancer immunosuppression |
5 |
|
candidiasis, oral - classification |
5 |
|
carcinoma - blood - diagnosis - genetics |
5 |
|
carcinoma, squamous cell - genetics - metabolism |
5 |
|
cell death - drug effects |
5 |
|
cells, cultured |
5 |
|
checkpoint inhibitors |
5 |
|
cheung chau island |
5 |
|
childhood lymphoma |
5 |
|
chromosomes, human, pair 1 - genetics |
5 |
|
chromosomes, human, pair 3 - ultrastructure |
5 |
|
clone cells |
5 |
|
complications |
5 |
|
cytokines - blood - genetics - metabolism |
5 |
|
cytotoxicity |
5 |
|
dental caries |
5 |
|
dental caries - classification |
5 |
|
diagnosis, differential |
5 |
|
diet |
5 |
|
dmf index |
5 |
|
dna - metabolism |
5 |
|
dose escalation |
5 |
|
dose-response relationship, drug |
5 |
|
double-negative b cells |
5 |
|
ebv‐encoded small rna |
5 |
|
enox2 |
5 |
|
epstein-barr virus infections - immunology - therapy |
5 |
|
epstein-barr virus nuclear antigens - immunology |
5 |
|
epstein–barr virus |
5 |
|
esophageal cancer surgery |
5 |
|
esophageal neoplasms - genetics - metabolism |
5 |
|
gene amplification |
5 |
|
gene expression profiling |
5 |
|
genes, tumor suppressor |
5 |
|
genome‐wide analysis |
5 |
|
health status indicators |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
idronoxil |
5 |
|
igra |
5 |
|
immunization, passive |
5 |
|
immunohistochemistry |
5 |
|
income |
5 |
|
local control |
5 |
|
longitudinal studies |
5 |
|
medical records |
5 |
|
memory t-cells |
5 |
|
metastatic brain tumours |
5 |
|
metronomic |
5 |
|
mice, nude |
5 |
|
molecular genetics |
5 |
|
molecular sequence numbers |
5 |
|
mortality |
5 |
|
mouth diseases - classification |
5 |
|
multidisciplinary management |
5 |
|
nasopharyngeal neoplasms - blood - diagnosis - genetics |
5 |
|
nasopharyngeal neoplasms - complications - radiotherapy |
5 |
|
nasopharyngeal neoplasms - drug therapy - mortality - pathology - radiotherapy |
5 |
|
nasopharyngeal neoplasms - drug therapy - mortality - radiotherapy |
5 |
|
nasopharyngeal neoplasms - immunology - pathology - therapy - virology |
5 |
|
nasopharyngeal neoplasms - mortality - pathology - radiotherapy |
5 |
|
nasopharyngeal neoplasms - mortality - radiotherapy |
5 |
|
nasopharyngeal neoplasms - pathology - radiotherapy - surgery |
5 |
|
nasopharyngeal neoplasms - virology |
5 |
|
neoadjuvant chemoradiation |
5 |
|
neoplasm recurrence, local |
5 |
|
neoplasm staging - methods |
5 |
|
neoplasm transplantation |
5 |
|
network meta-analysis |
5 |
|
oral cyclophosphamide |
5 |
|
palliative |
5 |
|
palliative care |
5 |
|
parotid gland - physiology - radiation effects |
5 |
|
parotid gland - radiation effects |
5 |
|
pericardial effusion |
5 |
|
periodontal attachment loss - classification |
5 |
|
periodontal diseases - classification |
5 |
|
periodontal index |
5 |
|
phenotype |
5 |
|
phospholipase c delta - biosynthesis - genetics - physiology |
5 |
|
pooled analysis |
5 |
|
precursor cell lymphoblastic leukemia-lymphoma - diagnosis - drug therapy - genetics |
5 |
|
psychology, social |
5 |
|
quality of life - psychology |
5 |
|
questionnaire |
5 |
|
questionnaires |
5 |
|
radiation injuries - etiology - prevention & control |
5 |
|
radiotherapy adverse effects |
5 |
|
radiotherapy, conformal - adverse effects |
5 |
|
radiotherapy, intensity-modulated |
5 |
|
randomized controlled clinical trial |
5 |
|
recurrent |
5 |
|
risk assessment |
5 |
|
root caries - classification |
5 |
|
saliva - secretion |
5 |
|
saliva electrolytes |
5 |
|
salivary glands - physiopathology - radiation effects |
5 |
|
sensitivity and specificity |
5 |
|
sequencing |
5 |
|
sex chromosome aberrations - diagnosis - genetics |
5 |
|
survival outcome |
5 |
|
systemic treatment |
5 |
|
tooth diseases - classification |
5 |
|
translocation, genetic |
5 |
|
treatment failure |
5 |
|
trismus - classification |
5 |
|
tuberculosis reactivation |
5 |
|
tumor markers, biological - analysis |
5 |
|
tumor suppressor proteins - blood - genetics - metabolism |
5 |
|
tumour board |
5 |
|
tyrosine kinase inhibitor |
5 |
|
viral matrix proteins - immunology |
5 |
|
xerostomia - classification |
5 |
|
xerostomia - etiology |
5 |
|
xerostomia - etiology - prevention & control |
5 |
|
xerostomia - prevention & control |
5 |
|
young adult |
5 |
|
acceptance |
4 |
|
adoptive immune transfer |
4 |
|
adoptive transfer |
4 |
|
animal |
4 |
|
antineoplastic agent |
4 |
|
antineoplastic agents - adverse effects |
4 |
|
antineoplastic agents - pharmacology |
4 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
4 |
|
anxiety |
4 |
|
assessment |
4 |
|
audiometry, pure-tone - methods |
4 |
|
biopsies |
4 |
|
bone |
4 |
|
bone necrosis |
4 |
|
brachytherapy |
4 |
|
cancer radiotherapy |
4 |
|
carcinoma - blood - mortality - pathology |
4 |
|
carcinoma - genetics |
4 |
|
carcinoma - pathology - radiotherapy |
4 |
|
carcinoma, squamous cell - complications - pathology - radiotherapy |
4 |
|
carcinoma, squamous cell - mortality - pathology - surgery - therapy |
4 |
|
carcinoma, squamous cell - mortality - pathology - therapy |
4 |
|
carcinoma, squamous cell - mortality - therapy |
4 |
|
carcinoma, squamous cell - pathology - therapy |
4 |
|
carcinoma, squamous cell - radiotherapy - surgery |
4 |
|
cardia |
4 |
|
cell adhesion |
4 |
|
cell culture |
4 |
|
cell cycle - drug effects |
4 |
|
cell movement |
4 |
|
cell proliferation |
4 |
|
cell survival |
4 |
|
cell survival - drug effects |
4 |
|
cell-free system |
4 |
|
cervical lymph node metastases |
4 |
|
child, preschool |
4 |
|
children |
4 |
|
chromosome deletion |
4 |
|
chromosomes, human, pair 3 |
4 |
|
chromosomes, human, pair 8 |
4 |
|
cisplatin - adverse effects |
4 |
|
cisplatin - pharmacology |
4 |
|
colon carcinoma cells |
4 |
|
colonic neoplasms - pathology |
4 |
|
contraceptive agents, male - toxicity |
4 |
|
cutaneous fistula - etiology |
4 |
|
cytokines - biosynthesis |
4 |
|
cytotoxic t cell |
4 |
|
cytotoxicity, immunologic |
4 |
|
deletion |
4 |
|
dna |
4 |
|
dna - blood - genetics |
4 |
|
dna fragmentation - drug effects |
4 |
|
dynamic contrast-enhanced magnetic resonance imaging |
4 |
|
effusion |
4 |
|
esophageal neoplasms - mortality - pathology - surgery - therapy |
4 |
|
esophageal neoplasms - mortality - pathology - therapy |
4 |
|
esophageal neoplasms - mortality - therapy |
4 |
|
esophageal neoplasms - pathology - therapy |
4 |
|
esophagectomy - methods |
4 |
|
fistula |
4 |
|
flow cytometry |
4 |
|
fluorescent antibody technique |
4 |
|
fluoride |
4 |
|
fluorodeoxyglucose f18 - diagnostic use - pharmacokinetics |
4 |
|
gastric cardia adenocarcinoma |
4 |
|
gelatinase |
4 |
|
genes, tumor suppressor - physiology |
4 |
|
genetic markers |
4 |
|
gossypol |
4 |
|
gossypol - toxicity |
4 |
|
grommet |
4 |
|
head and neck carcinomas |
4 |
|
hearing |
4 |
|
hearing loss, conductive - diagnosis - epidemiology - etiology |
4 |
|
hearing loss, sensorineural - etiology - physiopathology |
4 |
|
hematopoietic stem cells - immunology |
4 |
|
histologic remission |
4 |
|
hyperfractionation |
4 |
|
immune checkpoint inhibitor |
4 |
|
immune regulation |
4 |
|
immune-related endocrine dysfunction |
4 |
|
immunoglobulin a - chemistry |
4 |
|
implants |
4 |
|
implants and osteoblasts/osteoclasts |
4 |
|
intensity modulated radiation therapy |
4 |
|
killer cells, natural - immunology |
4 |
|
kinetics |
4 |
|
laryngeal neoplasms |
4 |
|
laryngeal neoplasms - radiotherapy - surgery |
4 |
|
laryngectomy |
4 |
|
laryngectomy - adverse effects |
4 |
|
liver metastases |
4 |
|
liver neoplasms - genetics - metabolism - secondary |
4 |
|
locally advanced recurrence |
4 |
|
lung neoplasms - genetics - metabolism - secondary |
4 |
|
lymph node excision |
4 |
|
lymphocyte activation - immunology |
4 |
|
magnetic resonance imaging |
4 |
|
malignancy |
4 |
|
manual contouring |
4 |
|
matrix metalloproteinase 2 - blood |
4 |
|
matrix metalloproteinase 9 - blood |
4 |
|
membrane glycoproteins - genetics - metabolism |
4 |
|
mice, scid |
4 |
|
micro-ct |
4 |
|
middle ear ventilation - methods |
4 |
|
mitochondria |
4 |
|
nasophanrygeal carcinoma |
4 |
|
nasopharyngeal neoplasms - blood - mortality - pathology |
4 |
|
nasopharyngeal neoplasms - blood - pathology |
4 |
|
nasopharyngeal neoplasms - complications - pathology - radiotherapy |
4 |
|
nasopharyngeal neoplasms - drug therapy - radiotherapy |
4 |
|
nasopharyngeal neoplasms - genetics |
4 |
|
nasopharyngeal neoplasms - immunology - mortality |
4 |
|
nasopharyngeal neoplasms - immunology - therapy - virology |
4 |
|
nasopharyngeal neoplasms - pathology - radiography |
4 |
|
nasopharyngeal neoplasms - pathology - radiotherapy |
4 |
|
nasopharynx |
4 |
|
natural history |
4 |
|
neck |
4 |
|
necrosis |
4 |
|
neoplasia |
4 |
|
nucleic acid hybridization |
4 |
|
nucleic acid hybridization - methods |
4 |
|
oral fistula - etiology |
4 |
|
osteopontin |
4 |
|
otitis media with effusion - complications - surgery |
4 |
|
otitis media with effusion - etiology |
4 |
|
palliative care - methods |
4 |
|
patient satisfaction |
4 |
|
peripheral blood monocyte |
4 |
|
pharyngeal diseases - etiology |
4 |
|
pharyngocutaneous |
4 |
|
physical and radiology |
4 |
|
plasma |
4 |
|
precision medicine |
4 |
|
prediction |
4 |
|
probability |
4 |
|
proteomics |
4 |
|
quantitative analysis |
4 |
|
radiation dosage |
4 |
|
radiation injuries - etiology |
4 |
|
radiation-sensitizing agents - adverse effects |
4 |
|
radiopharmaceuticals - diagnostic use - pharmacokinetics |
4 |
|
randomized |
4 |
|
randomized controlled trials as topic |
4 |
|
re-irradiation |
4 |
|
recist |
4 |
|
remission induction |
4 |
|
remission, spontaneous |
4 |
|
rhabdomyosarcoma |
4 |
|
rhabdomyosarcoma - mortality - pathology - therapy |
4 |
|
rna, messenger - genetics |
4 |
|
rna, viral - analysis |
4 |
|
s-1 (combination) |
4 |
|
saliva |
4 |
|
salivary dysfunction |
4 |
|
salvage therapy |
4 |
|
semiquantitative analysis |
4 |
|
sensorineural hearing loss |
4 |
|
severity of illness index |
4 |
|
sialoglycoproteins - blood |
4 |
|
single-cell sequencing |
4 |
|
soft tissue neoplasms - mortality - pathology - therapy |
4 |
|
standard fractionation |
4 |
|
stomach neoplasms |
4 |
|
sulfites - pharmacology |
4 |
|
target therapy |
4 |
|
thoracic neoplasms - pathology - therapy |
4 |
|
thyroid |
4 |
|
tissue array analysis |
4 |
|
toxicities |
4 |
|
treatment |
4 |
|
tumor doubling time |
4 |
|
tumor growth rate |
4 |
|
tumor markers, biological |
4 |
|
tumor microenvionment |
4 |
|
tumour stage |
4 |
|
untreated |
4 |
|
uroplakin ia |
4 |
|
vaccination |
4 |
|
volumetric evaluation |
4 |
|
wound healing |
4 |
|
xenograft model antitumor assays |
4 |
|
2-dimensional electrophoresis |
3 |
|
67lr |
3 |
|
actinin - analysis |
3 |
|
actn4 |
3 |
|
adenocarcinoma - epidemiology - genetics |
3 |
|
adenocarcinoma - genetics |
3 |
|
adipose tissue |
3 |
|
adoptive cell therapy |
3 |
|
adoptive immunotherapy |
3 |
|
afatinib |
3 |
|
alleles |
3 |
|
altered fractionation |
3 |
|
american joint committee on cancer stages |
3 |
|
anisotropy |
3 |
|
antibodies, monoclonal - diagnostic use |
3 |
|
antisense elements (genetics) |
3 |
|
apical papilla stem cell |
3 |
|
audiometry, pure-tone |
3 |
|
auditory threshold - radiation effects |
3 |
|
bart microrna |
3 |
|
beta-galactosidase - metabolism |
3 |
|
bevacizumab |
3 |
|
biological marker |
3 |
|
biological markers |
3 |
|
bone conduction - radiation effects |
3 |
|
bone neoplasms - drug therapy - epidemiology - pathology - surgery |
3 |
|
brain - pathology |
3 |
|
brain - radiation effects |
3 |
|
brain damage, chronic - diagnosis - etiology |
3 |
|
brain mapping |
3 |
|
brain neoplasms - radiotherapy |
3 |
|
brain stem - radiation effects |
3 |
|
brain tumor |
3 |
|
cadherins - blood |
3 |
|
cancer epidemiology |
3 |
|
cancer growth |
3 |
|
cancer incidence |
3 |
|
cancer inhibition |
3 |
|
cancer staging |
3 |
|
cancer survival |
3 |
|
cancer vaccine |
3 |
|
carcinogenesis |
3 |
|
carcinoma - drug therapy - mortality - pathology - radiotherapy |
3 |
|
carcinoma - drug therapy - radiotherapy |
3 |
|
carcinoma - enzymology - pathology |
3 |
|
carcinoma - genetics - mortality |
3 |
|
carcinoma, squamous cell - blood - mortality - pathology - therapy |
3 |
|
carcinoma, squamous cell - chemistry - pathology |
3 |
|
carcinoma, squamous cell - diagnosis - pathology - therapy |
3 |
|
carcinoma, squamous cell - epidemiology - genetics |
3 |
|
carcinoma, squamous cell - epidemiology - genetics - pathology |
3 |
|
carcinoma, squamous cell - genetics |
3 |
|
carcinoma, squamous cell - genetics - mortality - pathology |
3 |
|
carcinoma, squamous cell - genetics - pathology - radiotherapy |
3 |
|
carcinoma, squamous cell - genetics - pathology - surgery |
3 |
|
carcinoma, squamous cell - metabolism |
3 |
|
carcinoma, squamous cell - psychology - radiotherapy |
3 |
|
carotid arteries |
3 |
|
carrier proteins - genetics - physiology |
3 |
|
cell aging - drug effects |
3 |
|
cell cycle - drug effects - physiology |
3 |
|
cell cycle - radiation effects |
3 |
|
cell cycle proteins - metabolism |
3 |
|
cell division - drug effects |
3 |
|
cell division - drug effects - physiology |
3 |
|
cell function |
3 |
|
cell isolation |
3 |
|
cell survival - drug effects - physiology |
3 |
|
cerebellar neoplasms - diagnosis - drug therapy - radiotherapy |
3 |
|
cerebellar neoplasms - drug therapy - radiotherapy - surgery |
3 |
|
cerebellar neoplasms - pathology |
3 |
|
cerebellar neoplasms - pathology - radiotherapy |
3 |
|
cerebellar neoplasms - therapy |
3 |
|
cerebral cortex - pathology |
3 |
|
cerebrovascular disease |
3 |
|
cervical esophageal cancer |
3 |
|
cetuximab |
3 |
|
chemoradiation |
3 |
|
chromosome aberration |
3 |
|
chromosomes, human - genetics |
3 |
|
chromosomes, human, pair 11 - genetics |
3 |
|
chromosomes, human, pair 12 - genetics |
3 |
|
chromosomes, human, pair 14 - genetics |
3 |
|
chromosomes, human, pair 17 |
3 |
|
chromosomes, human, pair 20 |
3 |
|
chromosomes, human, pair 3 - genetics |
3 |
|
chromosomes, human, pair 4 |
3 |
|
chromosomes, human, pair 6 - genetics |
3 |
|
cisplatin - administration & dosage |
3 |
|
cisplatin - toxicity |
3 |
|
clinical target volume (ctv) |
3 |
|
coculture techniques |
3 |
|
cognition disorders - diagnosis - etiology |
3 |
|
cohort studies |
3 |
|
computed tomography |
3 |
|
cortical laminar necrosis |
3 |
|
course |
3 |
|
cranial irradiation |
3 |
|
cranial irradiation - adverse effects - methods |
3 |
|
craniopharyngioma |
3 |
|
ct contrast |
3 |
|
cyclin d1 |
3 |
|
cyclin d1 - genetics |
3 |
|
cyclin-dependent kinase inhibitor p16 |
3 |
|
cyclin-dependent kinases - antagonists & inhibitors |
3 |
|
cytotoxic t cells |
3 |
|
deafness |
3 |
|
deletion of 3p |
3 |
|
delineation |
3 |
|
diffusion magnetic resonance imaging |
3 |
|
diffusion tensor mri |
3 |
|
dna damage |
3 |
|
dna, neoplasm - analysis |
3 |
|
dna, neoplasm - genetics |
3 |
|
dna, viral - isolation & purification |
3 |
|
dominance, cerebral - physiology |
3 |
|
dose calculation |
3 |
|
dose-response |
3 |
|
dynamic [ 18f]fluoro-2-deoxy-d-glucose pet |
3 |
|
dysphagia |
3 |
|
ear, inner - radiation effects |
3 |
|
early detection |
3 |
|
ebv |
3 |
|
ebv dna |
3 |
|
endocrinopathy |
3 |
|
endoscopy |
3 |
|
enzyme induction - radiation effects |
3 |
|
enzyme linked immunosorbent assay |
3 |
|
ependymoma |
3 |
|
epidermal growth factor receptor mutation |
3 |
|
epstein-barr virus infections - blood - genetics - virology |
3 |
|
erlotinib |
3 |
|
esophageal neoplasm |
3 |
|
esophageal neoplasms - blood - mortality - pathology - therapy |
3 |
|
esophageal neoplasms - chemistry - pathology |
3 |
|
esophageal neoplasms - diagnosis - pathology - therapy |
3 |
|
esophageal neoplasms - epidemiology - genetics |
3 |
|
esophageal neoplasms - epidemiology - genetics - pathology |
3 |
|
esophageal neoplasms - genetics |
3 |
|
esophageal neoplasms - genetics - mortality - pathology |
3 |
|
esophageal neoplasms - genetics - pathology - surgery |
3 |
|
esophageal neoplasms - physiopathology - secretion |
3 |
|
fibroblasts - physiology - secretion |
3 |
|
fluorodeoxyglucose f18 - pharmacology |
3 |
|
fluorouracil - administration & dosage |
3 |
|
fluorouracil - toxicity |
3 |
|
frontal lobe - pathology - radiation effects |
3 |
|
frontal lobe - radiation effects |
3 |
|
g1 phase - radiation effects |
3 |
|
gamma rays |
3 |
|
gastroenterology |
3 |
|
gene deletion |
3 |
|
gene dosage - genetics |
3 |
|
genetic variation |
3 |
|
genome detection |
3 |
|
germ cell tumor |
3 |
|
gingival neoplasms - genetics - pathology |
3 |
|
glycoproteins - metabolism |
3 |
|
graves' ophthalmopathy |
3 |
|
gross target volume (gtv) |
3 |
|
guideline |
3 |
|
head and neck neoplasms - metabolism |
3 |
|
hearing loss, sensorineural - etiology |
3 |
|
hepatocellular carcinoma |
3 |
|
herpesvirus 4, human - classification - genetics - isolation & purification |
3 |
|
herpesvirus 4, human - genetics - isolation & purification |
3 |
|
herpesvirus 4, human - isolation & purification |
3 |
|
hypopharyngeal neoplasms - radiotherapy - surgery |
3 |
|
image enhancement |
3 |
|
image-guidance radiotherapy |
3 |
|
immune deficit |
3 |
|
inoperable |
3 |
|
intensity modulated radiotherapy |
3 |
|
intestinal mucosa - pathology - radiation effects |
3 |
|
jejunum - pathology - radiation effects - transplantation |
3 |
|
kras wild-type |
3 |
|
laryngeal preservation |
3 |
|
learning disorders - diagnosis - etiology |
3 |
|
local recurrence |
3 |
|
long-term irradiation |
3 |
|
medulloblastoma |
3 |
|
medulloblastoma - diagnosis - drug therapy - radiotherapy |
3 |
|
medulloblastoma - drug therapy - radiotherapy - surgery |
3 |
|
medulloblastoma - pathology |
3 |
|
medulloblastoma - pathology - radiotherapy |
3 |
|
medulloblastoma - therapy |
3 |
|
medulloblastoma survivors |
3 |
|
metastatic colorectal carcinoma |
3 |
|
microfilament proteins - analysis |
3 |
|
microrna |
3 |
|
micrornas |
3 |
|
micrornas - blood - genetics |
3 |
|
micrornas - chemistry - metabolism |
3 |
|
microsatellite instability |
3 |
|
microsatellite repeats |
3 |
|
microsatellite typing |
3 |
|
microscopy, electron, scanning |
3 |
|
microvilli - pathology - ultrastructure |
3 |
|
molecular biological classification |
3 |
|
mouth floor - pathology |
3 |
|
mouth neoplasms - genetics - pathology - radiotherapy |
3 |
|
multidisciplianry care |
3 |
|
multimodality treatment |
3 |
|
nasopharjngeal neoplasms |
3 |
|
nasopharyngeal neoplasms - blood - genetics - virology |
3 |
|
nasopharyngeal neoplasms - chemistry - diagnosis - radiotherapy |
3 |
|
nasopharyngeal neoplasms - diagnosis - radiotherapy - virology |
3 |
|
nasopharyngeal neoplasms - enzymology - pathology |
3 |
|
nasopharyngeal neoplasms - epidemiology - mortality - pathology |
3 |
|
nasopharyngeal neoplasms - ethnology - pathology - radiotherapy |
3 |
|
nasopharyngeal neoplasms - genetics - mortality |
3 |
|
nasopharyngeal neoplasms - immunology - pathology |
3 |
|
nasopharyngeal neoplasms - metabolism - pathology - radionuclide imaging - therapy |
3 |
|
nasopharyngeal neoplasms - metabolism - radionuclide imaging |
3 |
|
nasopharyngeal neoplasms - metabolism - radiotherapy |
3 |
|
nasopharyngeal neoplasms - mortality - radiography - radiotherapy |
3 |
|
nasopharyngeal neoplasms - psychology - radiotherapy |
3 |
|
neoadjuvant chemoradiation therapy |
3 |
|
neoplasm invasiveness |
3 |
|
neoplasm invasiveness - pathology |
3 |
|
neoplasm invasiveness - physiopathology |
3 |
|
neoplasm metastasis - genetics |
3 |
|
neoplasm proteins - metabolism |
3 |
|
neoplasm recurrence, local - epidemiology |
3 |
|
neoplasm recurrence, local - mortality - radiography - radiotherapy |
3 |
|
neoplasms, germ cell and embryonal - radiotherapy |
3 |
|
nerve fibers, myelinated - drug effects - pathology - radiation effects |
3 |
|
neurotoxicity |
3 |
|
neurotoxicity syndromes |
3 |
|
novel therapy |
3 |
|
oligonucleotide array sequence analysis |
3 |
|
oncogenes |
3 |
|
oral |
3 |
|
oropharyngeal neoplasms - genetics - pathology |
3 |
|
osteosarcoma |
3 |
|
osteosarcoma - drug therapy - epidemiology - pathology - surgery |
3 |
|
outcome |
3 |
|
p53 |
3 |
|
palatal neoplasms - genetics - pathology |
3 |
|
parietal lobe - pathology - radiation effects |
3 |
|
parietal lobe - radiation effects |
3 |
|
parotid gland - physiopathology - radiation effects |
3 |
|
pathogenesis |
3 |
|
pattern of failure |
3 |
|
persistent disease |
3 |
|
pet/ct |
3 |
|
pharynx |
3 |
|
positron emission tomography-computed tomography |
3 |
|
positron-emission tomography - methods |
3 |
|
positron-emission tomography and computed tomography |
3 |
|
positron-emission tomography and computed tomography - methods |
3 |
|
postoperative care |
3 |
|
predictive value of tests |
3 |
|
protein array analysis |
3 |
|
psychological response |
3 |
|
psychosocial impact |
3 |
|
quantitative pcr |
3 |
|
radiation injuries - diagnosis |
3 |
|
radiation recall |
3 |
|
radiation tolerance |
3 |
|
radioembolization |
3 |
|
radiotherapy planning, computer-assisted |
3 |
|
radiotherapy, intensity-modulated - adverse effects - methods |
3 |
|
real-time polymerase chain reaction |
3 |
|
receptor, igf type 1 - metabolism |
3 |
|
receptors, antigen, t-cell, gamma-delta - analysis |
3 |
|
receptors, laminin - analysis |
3 |
|
recombinant proteins - metabolism |
3 |
|
recovery of function |
3 |
|
reference values |
3 |
|
reirradiation |
3 |
|
reproducibility of results |
3 |
|
retro-orbital irradiation |
3 |
|
rna, messenger - metabolism |
3 |
|
rna, viral - blood - genetics |
3 |
|
saliva - chemistry |
3 |
|
salivation - physiology - radiation effects |
3 |
|
screening |
3 |
|
soluble e-cadherin |
3 |
|
spectral karyotyping |
3 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
3 |
|
staging |
3 |
|
standardized uptake value |
3 |
|
stomach neoplasms - epidemiology - genetics |
3 |
|
survivors |
3 |
|
t cells |
3 |
|
t-lymphocytes - immunology |
3 |
|
telomerase |
3 |
|
telomerase - metabolism |
3 |
|
tnm staging |
3 |
|
total lesion glycolysis |
3 |
|
transarterial chemoembolization |
3 |
|
transcriptomics |
3 |
|
transfection |
3 |
|
tumor burden |
3 |
|
tumor cells, cultured - enzymology - radiation effects |
3 |
|
tumor heterogeneity |
3 |
|
tumor immunity |
3 |
|
tumor invasion |
3 |
|
tumor markers, biological - chemistry - metabolism |
3 |
|
tumor markers, biological - genetics |
3 |
|
tumor metastasis |
3 |
|
tumor stem cell assay |
3 |
|
tumor suppressor protein p53 - drug effects - metabolism - physiology |
3 |
|
tumor suppressor protein p53 - genetics |
3 |
|
tyrosine-kinase inhibitor |
3 |
|
white-matter diffusion anisotrophy |
3 |
|
wnt signaling pathway - physiology |
3 |
|
wnt2 protein - physiology - secretion |
3 |
|
γδ t cells |
3 |
|
5-fluorouracil |
2 |
|
acute emesis |
2 |
|
adenocarcinoma |
2 |
|
adenocarcinoma - diagnosis - mortality - surgery |
2 |
|
adipocytes - cytology - drug effects - radiation effects |
2 |
|
adipogenesis - radiation effects |
2 |
|
adjuvant |
2 |
|
administration, oral |
2 |
|
akr7a3 |
2 |
|
alkaline phosphatase - metabolism |
2 |
|
alopecia - chemically induced |
2 |
|
american joint committee on cancer (ajcc) |
2 |
|
amino acid sequence |
2 |
|
antibodies, monoclonal - immunology |
2 |
|
antibodies, viral - immunology |
2 |
|
antibody specificity |
2 |
|
antiemesis |
2 |
|
antiemetics - pharmacology - therapeutic use |
2 |
|
antigens, viral - analysis |
2 |
|
antigens, viral - immunology |
2 |
|
apoptosis regulatory proteins |
2 |
|
azacitidine - analogs & derivatives - pharmacology |
2 |
|
base sequence |
2 |
|
biochemistry |
2 |
|
biological markers - blood |
2 |
|
biology |
2 |
|
bleomycin - administration & dosage |
2 |
|
body fluids - chemistry |
2 |
|
body motions |
2 |
|
bone and bones - drug effects - metabolism - radiation effects |
2 |
|
bone marrow cells - cytology - drug effects - radiation effects |
2 |
|
brachytherapy - adverse effects - methods |
2 |
|
brain necrosis |
2 |
|
breast |
2 |
|
breast neoplasms - physiopathology - radiotherapy - surgery |
2 |
|
calcium - metabolism |
2 |
|
calcium-calmodulin-dependent protein kinases - biosynthesis - blood - genetics |
2 |
|
cancer progression |
2 |
|
carcinoma - blood - enzymology |
2 |
|
carcinoma - blood - genetics - metabolism |
2 |
|
carcinoma - diagnosis - pathology |
2 |
|
carcinoma - diagnosis - physiopathology |
2 |
|
carcinoma - diagnosis - therapy |
2 |
|
carcinoma - drug therapy - pathology - radiography - radiotherapy |
2 |
|
carcinoma - drug therapy - pathology - radiotherapy |
2 |
|
carcinoma - mortality - radiotherapy - secondary - surgery |
2 |
|
carcinoma - pathology - radiography - therapy |
2 |
|
carcinoma - pathology - radiotherapy - secondary |
2 |
|
carcinoma - radiotherapy - surgery - virology |
2 |
|
carcinoma, hepatocellular - genetics |
2 |
|
carcinoma, papillary - pathology - virology |
2 |
|
carcinoma, squamous cell - drug therapy - genetics - radiotherapy |
2 |
|
carcinoma, squamous cell - genetics - pathology |
2 |
|
cell differentiation - drug effects - radiation effects |
2 |
|
cell line, transformed |
2 |
|
cell proliferation - drug effects - radiation effects |
2 |
|
cell-free |
2 |
|
cervical metastases |
2 |
|
cgh |
2 |
|
chemoresistance |
2 |
|
chest tumors |
2 |
|
chromosome aberrations - genetics |
2 |
|
chromosome disorders |
2 |
|
chromosomes, human |
2 |
|
classification and regression tree (cart) |
2 |
|
computed tomography images |
2 |
|
confidence intervals |
2 |
|
craniospinal irradiation |
2 |
|
cross-over studies |
2 |
|
cross-sectional imaging |
2 |
|
cytogenetic analysis |
2 |
|
decision trees |
2 |
|
dexamethasone |
2 |
|
dexamethasone - pharmacology - therapeutic use |
2 |
|
diagnosis |
2 |
|
differentiation |
2 |
|
distant metastasis |
2 |
|
dna, neoplasm - analysis - blood - chemistry |
2 |
|
dna, viral - analysis - isolation & purification |
2 |
|
dna, viral - blood |
2 |
|
dna-binding proteins - genetics |
2 |
|
dose |
2 |
|
dose-volume histograms |
2 |
|
dosimetric changes |
2 |
|
dosimetric parameter |
2 |
|
drug resistance, multiple |
2 |
|
ear, middle - pathology - radiography - surgery |
2 |
|
early stage |
2 |
|
endoscopy - methods |
2 |
|
epirubicin - administration & dosage |
2 |
|
epstein-barr virus (ebv) |
2 |
|
epstein-barr virus infections - blood |
2 |
|
epstein-barr virus infections - virology |
2 |
|
epstein-barr virus, dna |
2 |
|
equipment failure |
2 |
|
esophageal |
2 |
|
esophageal adenocarcinoma |
2 |
|
esophageal neoplasms - genetics - pathology |
2 |
|
esophagogastric |
2 |
|
esophagogastric junction adenocarcinoma |
2 |
|
fluorescence spectroscopy |
2 |
|
forced expiratory flow rates - radiation effects |
2 |
|
forecasting |
2 |
|
foxo1 |
2 |
|
fractionation |
2 |
|
gca |
2 |
|
genes, viral |
2 |
|
genetic alterations |
2 |
|
genetics |
2 |
|
glossectomy |
2 |
|
gold radioisotopes - therapeutic use |
2 |
|
granisetron |
2 |
|
granisetron - pharmacology - therapeutic use |
2 |
|
hcc |
2 |
|
head and neck neoplasms - drug therapy |
2 |
|
head and neck neoplasms - pathology |
2 |
|
head-and-neck cancer |
2 |
|
hepatitis, chronic - genetics |
2 |
|
herpesviridae infections - complications - pathology |
2 |
|
histone-lysine n-methyltransferase |
2 |
|
hodgkin disease - virology |
2 |
|
hodgkin's disease |
2 |
|
human |
2 |
|
ifosfamide |
2 |
|
ifosfamide - administration & dosage |
2 |
|
immunoblastic lymphadenopathy - epidemiology - pathology - radiography - therapy |
2 |
|
in situ hybridization |
2 |
|
in vivo diagnosis |
2 |
|
individual patient data |
2 |
|
indoles - pharmacology - therapeutic use |
2 |
|
infusions, intravenous |
2 |
|
injections, intravenous |
2 |
|
intensity-modulated |
2 |
|
interphase - genetics |
2 |
|
interruption |
2 |
|
interstitial implantation |
2 |
|
irradiation |
2 |
|
keratolytic agents - pharmacology |
2 |
|
latent membrane protein (lmp 1) |
2 |
|
leucovorin |
2 |
|
leucovorin - administration & dosage |
2 |
|
lif spectroscopy |
2 |
|
linac |
2 |
|
linear models |
2 |
|
liver neoplasms - genetics |
2 |
|
local |
2 |
|
loco-regional |
2 |
|
lung - physiopathology - radiation effects - radiography |
2 |
|
lymph nodes - pathology - radiography |
2 |
|
lymphatic metastasis - pathology |
2 |
|
lymphocytes - virology |
2 |
|
lymphoma |
2 |
|
lymphoma, b-cell - pathology - virology |
2 |
|
lymphoma, non-hodgkin - pathology - virology |
2 |
|
lymphoma, t-cell, peripheral - virology |
2 |
|
lymphopenia |
2 |
|
m & t rinsing fluid |
2 |
|
m2 macrophage |
2 |
|
management |
2 |
|
mass spectrometry |
2 |
|
mesenchymal stem cell transplantation |
2 |
|
mesenchymal stem cells - cytology - drug effects - radiation effects |
2 |
|
mesenchymal stromal cells |
2 |
|
meta-analysis |
2 |
|
metastatic lymph nodes |
2 |
|
methotrexate - administration & dosage |
2 |
|
metoclopramide |
2 |
|
microchip analytical procedures |
2 |
|
models, theoretical |
2 |
|
molecular sequence data |
2 |
|
monoclonal antibodies |
2 |
|
mouth |
2 |
|
mouth - metabolism |
2 |
|
mouth neoplasms - drug therapy - genetics - radiotherapy |
2 |
|
mouthwashes |
2 |
|
multidrug resistance |
2 |
|
mutations |
2 |
|
nasopharyngeal neoplasms - blood - classification - diagnosis |
2 |
|
nasopharyngeal neoplasms - blood - enzymology |
2 |
|
nasopharyngeal neoplasms - blood - genetics - metabolism |
2 |
|
nasopharyngeal neoplasms - diagnosis - mortality - surgery |
2 |
|
nasopharyngeal neoplasms - diagnosis - pathology |
2 |
|
nasopharyngeal neoplasms - diagnosis - physiopathology |
2 |
|
nasopharyngeal neoplasms - diagnosis - therapy |
2 |
|
nasopharyngeal neoplasms - drug therapy - pathology - radiography - radiotherapy |
2 |
|
nasopharyngeal neoplasms - drug therapy - pathology - radiotherapy |
2 |
|
nasopharyngeal neoplasms - drug therapy - radiography |
2 |
|
nasopharyngeal neoplasms - genetics - pathology |
2 |
|
nasopharyngeal neoplasms - pathology - radiography - therapy |
2 |
|
nasopharyngeal neoplasms - physiopathology - radiotherapy |
2 |
|
nasopharyngeal neoplasms - radiotherapy - surgery - virology |
2 |
|
nasopharyngeal neoplasms [*drug therapy; mortality; radiotherapy] |
2 |
|
nasopharyngeal swab |
2 |
|
nasopharynx - anatomy & histology - pathology |
2 |
|
nasopharynx - cancer - treatment. |
2 |
|
nasopharynx - pathology |
2 |
|
nasopharynx - physiology |
2 |
|
nasopharynx - surgery |
2 |
|
neck - pathology |
2 |
|
neoadjuvant |
2 |
|
neoplasm proteins - blood |
2 |
|
neoplasm recurrence |
2 |
|
neoplasm recurrence, local - diagnosis - mortality - surgery |
2 |
|
neoplasm recurrence, local - drug therapy |
2 |
|
neoplasm recurrence, local - pathology |
2 |
|
neoplasm recurrence, local - pathology - radiotherapy |
2 |
|
neoplasm recurrence, local - surgery - virology |
2 |
|
nodal necrosis |
2 |
|
nuclear proteins - genetics |
2 |
|
nucleic acid amplification techniques |
2 |
|
oncogene proteins, viral - analysis - chemistry - genetics - immunology |
2 |
|
ondansetron |
2 |
|
ondansetron - pharmacology - therapeutic use |
2 |
|
oral cancers |
2 |
|
osteogenesis - drug effects - radiation effects |
2 |
|
overall treatment time |
2 |
|
overview |
2 |
|
p-glycoprotein |
2 |
|
p-glycoprotein - analysis |
2 |
|
palliative chemotherapy |
2 |
|
paranasopharyngeal extension |
2 |
|
patient compliance |
2 |
|
patterns of failure |
2 |
|
perioperative |
2 |
|
pharyngectomy - methods |
2 |
|
pharynx - metabolism |
2 |
|
platinum compounds - administration & dosage |
2 |
|
pneumocystis jiroveci |
2 |
|
preoperative |
2 |
|
principal component analysis |
2 |
|
proliferation |
2 |
|
radiation dose |
2 |
|
radiation injuries - etiology - physiopathology |
2 |
|
radiation injuries - pathology |
2 |
|
radiation injuries - prevention & control |
2 |
|
radiology |
2 |
|
radiosurgery |
2 |
|
radiosurgery - methods |
2 |
|
radiotherapy and tmj and masticatory muscles |
2 |
|
radiotherapy effects |
2 |
|
radiotherapy planning |
2 |
|
radiotherapy, intensity-modulated - methods |
2 |
|
randomized trial |
2 |
|
recurrent nasopharyngeal carcinoma |
2 |
|
respiration disorders - etiology - physiopathology |
2 |
|
retinoic acid |
2 |
|
retropharyngeal lymph node |
2 |
|
risk |
2 |
|
salvage surgery |
2 |
|
self-assessment |
2 |
|
sequence deletion |
2 |
|
smell - physiology |
2 |
|
spectrometry, fluorescence - instrumentation - methods |
2 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization - methods |
2 |
|
stereotaxic techniques |
2 |
|
stomatitis - etiology |
2 |
|
sulfites - metabolism |
2 |
|
surface properties |
2 |
|
surface-enhanced laser desorption/ionization (seldi) |
2 |
|
surgical salvage |
2 |
|
suv |
2 |
|
tegafur - administration & dosage |
2 |
|
temporal lobe - pathology - radiation effects |
2 |
|
thyroid neoplasms - pathology - virology |
2 |
|
thyroiditis, autoimmune - pathology - virology |
2 |
|
time |
2 |
|
timing of interruption |
2 |
|
tongue |
2 |
|
tongue neoplasms - mortality - pathology - radiotherapy - surgery |
2 |
|
total lung capacity - radiation effects |
2 |
|
transcription factors - genetics |
2 |
|
transcription, genetic |
2 |
|
tretinoin - pharmacology |
2 |
|
tropisetron |
2 |
|
tumor control probability |
2 |
|
tumor markers, biological - analysis - blood |
2 |
|
tumor stage |
2 |
|
tumor suppressor protein p53 - analysis |
2 |
|
tumor virus infections - complications - pathology |
2 |
|
tumor volume |
2 |
|
uracil - administration & dosage |
2 |
|
vincristine - administration & dosage |
2 |
|
viral matrix proteins - analysis - chemistry - genetics - immunology |
2 |
|
vital capacity - radiation effects |
2 |
|
volumetric changes |
2 |
|
vomiting - chemically induced - prevention & control |
2 |
|
x-rays |
2 |
|
3-d conformal radiotherapy |
1 |
|
4d dose calculation |
1 |
|
4d optimization |
1 |
|
adenocarcinoma - pathology - radiotherapy - surgery |
1 |
|
air |
1 |
|
antineoplastic agents, hormonal - adverse effects - therapeutic use |
1 |
|
arteriosclerosis |
1 |
|
asia |
1 |
|
atherosclerotic plaque |
1 |
|
biophysical phenomena |
1 |
|
biophysics |
1 |
|
blood flow velocity |
1 |
|
body burden |
1 |
|
breast cancer |
1 |
|
breast neoplasms - drug therapy - metabolism - mortality - pathology |
1 |
|
breast neoplasms - drug therapy - radiotherapy - surgery |
1 |
|
breast neoplasms - mortality - therapy |
1 |
|
breast neoplasms - radiotherapy |
1 |
|
carcinoma, intraductal, noninfiltrating - drug therapy - radiotherapy - surgery |
1 |
|
carotid atherosclerosis |
1 |
|
carotid plaque score |
1 |
|
cell-free circulating dna |
1 |
|
central nervous system |
1 |
|
clinical protocols |
1 |
|
computer simulation |
1 |
|
cone beam computed tomography |
1 |
|
cone-beam computed tomography - methods - standards |
1 |
|
conformity index |
1 |
|
conventional radiotherapy |
1 |
|
cyberknife |
1 |
|
diagnostic imaging |
1 |
|
diagnostic imaging - methods |
1 |
|
distant metastases |
1 |
|
dna hypermethylation |
1 |
|
dose evaluation |
1 |
|
elastography |
1 |
|
esophageal neoplasms - pathology - radiotherapy |
1 |
|
esophageal neoplasms - radiography - radiotherapy |
1 |
|
estrogen antagonists - therapeutic use |
1 |
|
ethmoid sinus - pathology - radiation effects - surgery |
1 |
|
ethmoid sinus cancer |
1 |
|
extended adjuvant chemotherapy |
1 |
|
fertility preservation |
1 |
|
forced expiratory volume - physiology |
1 |
|
four-dimensional dosimetry |
1 |
|
guidelines |
1 |
|
head - radiography |
1 |
|
head and neck cancer |
1 |
|
head and neck neoplasms - radiotherapy |
1 |
|
heart - radiation effects |
1 |
|
high resolution computed tomography |
1 |
|
hypofractionated stereotactic lung radiotherapy |
1 |
|
hypothalamo-hypophyseal system - radiation effects |
1 |
|
image-guided radiation therapy |
1 |
|
imrt planning |
1 |
|
infant |
1 |
|
intrafractional organ motion |
1 |
|
intrafractional variation of tumor motion |
1 |
|
inverse planning |
1 |
|
loco-regional control |
1 |
|
loco-regional relapse |
1 |
|
lung |
1 |
|
lung - radiation effects |
1 |
|
lung - radiation effects - radiography |
1 |
|
lung neoplasms - radiography - radiotherapy |
1 |
|
lung neoplasms - radiography - radiotherapy - surgery |
1 |
|
lymph node |
1 |
|
mastectomy, segmental |
1 |
|
monte carlo dose calculation |
1 |
|
msp |
1 |
|
multicenter studies as topic - statistics and numerical data |
1 |
|
nasopharyngeal neoplasms - epidemiology - radiotherapy |
1 |
|
nasopharyngeal neoplasms - physiopathology - radiography - radiotherapy |
1 |
|
nasopharyngeal neoplasms - radiography - radiotherapy |
1 |
|
nasopharyngeal neoplasms - radiotherapy - ultrasonography |
1 |
|
neck - radiography |
1 |
|
neoplasm metastasis - prevention & control |
1 |
|
neoplasms |
1 |
|
neurosurgery |
1 |
|
noncoplanar beams |
1 |
|
normal |
1 |
|
on-board imager |
1 |
|
organ size |
1 |
|
paranasal sinus neoplasms - pathology - radiotherapy - surgery |
1 |
|
paraoxonase |
1 |
|
parotid gland |
1 |
|
parotid gland - blood supply - injuries - pathology - ultrasonography |
1 |
|
parotid gland - pathology - physiopathology - radiation effects - radiography |
1 |
|
parotid gland - pathology - ultrasonography |
1 |
|
particle accelerators |
1 |
|
patient dose |
1 |
|
pelvis - radiography |
1 |
|
peripheral dose |
1 |
|
peroxiredoxin |
1 |
|
phantoms, imaging |
1 |
|
photons - therapeutic use |
1 |
|
pituitary gland - radiation effects |
1 |
|
pituitary shield |
1 |
|
pituitary-adrenal system - radiation effects |
1 |
|
planning objective prediction |
1 |
|
pregnancy |
1 |
|
proportional hazards models |
1 |
|
prostatic neoplasms - radiography - radiotherapy |
1 |
|
protein profiling |
1 |
|
radiation effects |
1 |
|
radiation injuries |
1 |
|
radiation injuries - etiology - pathology - ultrasonography |
1 |
|
radiation injuries - radiography |
1 |
|
radiation protection |
1 |
|
radiation therapy planning |
1 |
|
radiometry - methods |
1 |
|
radiotherapy - adverse effects |
1 |
|
radiotherapy - adverse effects - methods |
1 |
|
radiotherapy planning, computer-assisted - methods |
1 |
|
radiotherapy planning, computer-assisted - statistics and numerical data |
1 |
|
radiotherapy, adjuvant - statistics and numerical data |
1 |
|
radiotherapy, computer-assisted - instrumentation - methods |
1 |
|
radiotherapy, conformal |
1 |
|
radiotherapy, conformal - adverse effects - methods |
1 |
|
radiotherapy, conformal - methods |
1 |
|
radiotherapy, high-energy |
1 |
|
radiotherapy, intensity-modulated - statistics and numerical data |
1 |
|
randomized controlled trials as topic - statistics and numerical data |
1 |
|
receptors, estrogen - metabolism |
1 |
|
receptors, progesterone - metabolism |
1 |
|
regression analysis |
1 |
|
respiratory distress syndrome, adult - radiography |
1 |
|
robotic target tracking |
1 |
|
robotics |
1 |
|
salivary glands - radiation effects |
1 |
|
sbrt |
1 |
|
sex characteristics |
1 |
|
single nucleotide polymorphisms |
1 |
|
software validation |
1 |
|
sphenoid sinus - pathology - radiation effects |
1 |
|
spinal cord - radiation effects |
1 |
|
squamous cell carcinoma antigen 1 |
1 |
|
stereotactic body radiotherapy |
1 |
|
tamoxifen - adverse effects - therapeutic use |
1 |
|
thermoluminescence dosimeters |
1 |
|
thermoluminescent dosimetry - instrumentation - methods |
1 |
|
three-dimensional imaging |
1 |
|
tracking |
1 |
|
transgelin |
1 |
|
tumor |
1 |
|
tumor suppressor genes |
1 |
|
tumor-associated proteins |
1 |
|
two-dimensional gel electrophoresis |
1 |
|
ultrasonography |
1 |
|
ultrasonography, doppler - methods |
1 |
|
ultrasound |
1 |
|
vascular resistance |
1 |
|
vital capacity - physiology |
1 |
|
volumetric-modulated arc radiotherapy |
1 |
|
whole-body counting - methods |
1 |
|
xerostomia - diagnosis - etiology |
1 |
|
xerostomia - etiology - pathology - radiography |
1 |
|
xerostomia - etiology - ultrasonography |
1 |
